Refine by
Car T Cell Articles & Analysis: Older
55 news found
The company's portfolio includes immune checkpoint proteins, CAR-T cell targets, CD antigens, fluorescent-labeled recombinant proteins, PROTAC targets, and more. ...
Beyond these technologies, CD Formulation's services extend to polymer in-situ forming implant systems and CAR-T/NK cell development for drug delivery systems. These services contribute to the development of innovative approaches that overcome challenges associated with specific drugs or therapeutic modalities. ...
In the rapidly evolving field of drug delivery systems, novel therapies are continuously being developed to enhance the effectiveness and precision of treatment. CAR-T (chimeric antigen receptor T-cell) and CAR-NK (chimeric antigen receptor natural killer cell) therapies involve genetically ...
Specifically, it covers Cartherics’ chimeric antigen receptor (CAR) targeting tumor-associated glycoprotein-72 (TAG-72), along with T cells bearing the TAG-72 CAR. ...
INB-100 continued to demonstrate durable morphologic complete responses in the Phase 1 clinical trial in patients with leukemia; on track to announce additional data at upcoming ASH annual meeting. Partnered with the Dunbar CAR T-Cell Program at the University of Louisville as the GMP manufacturing center for INB-400. ...
The Peter MacCallum Cancer Centre (“Peter Mac”) and Cartherics Pty Ltd (“Cartherics”) announced today they have entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics’ proprietary autologous CAR-T cell therapy (CTH-001) for the treatment of cutaneous ...
Over the course of the next five years, we aim to build a portfolio comprising: over 10 assets in lead optimization and five in preclinical development across different modalities (small molecules, cell therapy, biologics), five pivotal-stage candidates forming a solid late-stage pipeline in immunology and cell therapy, and a growing commercial presence with ...
By inhibiting VISTA, an immune checkpoint receptor mainly expressed on MDSC (Myeloid-Derived Suppressor Cells) and Tregs (regulatory T cells), it can play a pivotal role in maintaining the immunosuppressive environment around the tumor cells. ...
“The Dunbar CAR T-Cell Program has a superb facility designed specifically to advance the development of promising T-cell therapies. ...
The capital raise enables Carina to complete its Investigational New Drug (IND) enabling studies and initiate a CAR-T clinical trial of our LGR5 CAR-T cell for patients with advanced colorectal (bowel) cancer. ...
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has appointed Ms Cassandra Harrison to the position of Vice President (VP) Clinical Operations and Data Management. ...
Chimeric Therapeutics (ASX:CHM, “Chimeric”), a clinical-stage cell therapy company and an Australian leader in cell therapy, is pleased to announce that it has expanded its license agreement with the University of Pennsylvania (Penn) related to CDH17 chimeric antigen receptor (CAR) therapies. Under the amended agreement, Chimeric has ...
Poster 159: Developing placental CD34+-derived natural killer cells with high affinity cleavage resistant CD16 (CYNK-101) and Cetuximab for enhanced therapy of EGFR+ non-small cell lung and head and neck cancers” Highlights: CYNK-101 is a cryopreserved off the shelf allogeneic NK cell product, overexpressing a high IgG binding affinity, ...
“As we continue to advance clinical development of our pipeline, we believe our addition to the Russell indexes will broaden awareness of the biological advantages of placental-derived cell therapies, including both greater proliferative performance and natural immune tolerance. We remain committed to leading the next evolution of cellular therapies for the treatment of ...
(Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. ...
Highlights Melbourne-based contract development and manufacturing organisation Cell Therapies will manufacture Carina Biotech’s LGR5 CAR-T cells for a first-in-human clinical trial for patients with advanced colorectal (bowel) cancer. Carina’s CAR-T cells are ...
Jean-Yves Blay, independent Director; Laurence Espinasse, Director; Sandrine Flory, Director (TSGH representative); Benoît Habert, independent Director; Marie Landel, independent Director; Maya Saïd, independent Director. ...
(Nasdaq: CELU) (“Celularity”), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 4,054,055 shares of its Class A common stock at a purchase price of $7.40 per ...
Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually at the ...
Date and Time: May 18, 2022, 5:30 p.m. to 6:30 p.m. ET Title: Armoring T-cells with regulatable, membrane tethered cytokines using improved drug-responsive domain technology (cytoDRiVE®) Presenter: Dr. ...